Sign In
Section Navigation
Common TitlePOWER 3
Official Title An Open Label Trial of Darunavir (TMC114)/RTV in HIV-1 Infected, Treatment-experienced Subjects.
Phase Phase II
ClinicalTrials.gov NCT00081588
Categories Resistance/Virological FailureTreatment-Experienced
Funding
IndustryTibotec Pharmaceuticals, Ireland
References
  • ArastĂ©h K, Yeni P, Pozniak A, et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther. 2009;14:859-64.
    [PubMed Abstract]
  • de Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses. 2008;24:379-88.
    [PubMed Abstract]
  • Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr. 2007;46:24-31.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.